Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Collaboration › Details

Thermo Fisher–ToolGen: CRISPR technology, 201503– license ww rights for research applications + HTS + Dx + bioproduction


Period Period 2015-03-10
Region Region ALL
Organisations Partner, 1st Thermo Fisher Scientific Inc., Carlsbad, CA (Life Technologies business)
  Group Thermo Fisher (Group)
  Partner, 2nd ToolGen, Inc. (KONEX:199800)
Products Product CRISPR gene editing technology
  Product 2 TALEN® technology (Transcription Activator-Like Effector Nuclease)
Person Person Kim, Jin Soo (Seoul National Univ 201503 + Co-founder of ToolGen)

Thermo Fisher Scientific Inc.. (3/10/15). "Press Release: ToolGen, Inc. and Thermo Fisher Scientific Sign License Agreement for CRISPR/Cas9 Genome Editing Technology". Carlsbad, CA & Seoul.

ToolGen, Inc. (, KONEX:199800), a Korean biotechnology company with a focus in the genome editing space, and Thermo Fisher Scientific (,), the world leader in serving science, announced today an agreement under which ToolGen, Inc. will license its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific.

Thermo Fisher will utilize the technology to develop and market new CRISPR reagent kits, bringing new tools to researchers working in the rapidly growing field. The kits will augment Thermo Fisher’s strong portfolio in the complementary transcription activator-like effector nucleases (TALEN) technique.

Scientists have begun to use the CRISPR/Cas9 system, which was originally identified as part of the adaptive immune system of many bacterial species, for targeted genome engineering in eukaryotic cells. The licensed intellectual property is based, in part, on the discovery by Dr. Jin Soo Kim, a researcher at Seoul National University and co-founder of ToolGen, Inc., that the CRISPR/Cas9 system can be used to engineer cells found in multicellular organisms such as mammals, plants and fungi.

Under the terms of the agreement, Thermo Fisher Scientific is granted a worldwide license for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bioproduction. Thermo Fisher Scientific also has the right to grant sublicenses in each of these fields. ToolGen retains its rights in broad areas including high throughput screening, diagnostics, bioproduction, plant biotechnology and gene/cell therapy.

“This license agreement further strengthens the relationship between ToolGen and Thermo Fisher in the area of genome editing,” Jongmoon Kim, the CEO of ToolGen, Inc., stated. “It shows the importance of ToolGen’s IP within the complex CRISPR IP landscape and demonstrates our focus on establishing global partnerships to maximize the potential of our technologies for a wide array of applications.”

“Genome editing technologies are among the most exciting innovations in the life science in recent years, truly enabling scientists to understand gene function, the underlying molecular mechanisms for cell function and disease onset and progression” said Helge Bastian, vice president and general manager of synthetic biology at Thermo Fisher Scientific. “This license agreement, as part of Thermo Fisher Scientific’s larger strategy, underlines Thermo Fisher Scientific’s commitment to invest into further developing these genome editing technologies into groundbreaking products that enable our customers to make our world healthier, cleaner and safer.”

ToolGen previously granted Thermo Fisher Scientific a license to technology related to Thermo Fisher Scientific’s GeneArt® Genomic Cleavage Selection Kit, which provides a rapid and reliable way to detect the functionality of TALENs®, CRISPRs, ZFNs or any other engineered nuclease in transfected cells, as well as enriching for modified live cells.

About ToolGen, Inc.

ToolGen, Inc. is a publicly traded biotechnology company focused on the development and application of genome editing technologies. It creates, and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of our innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

Photos/Multimedia Gallery Available:



Dr. Seokjoong Kim, 82-10-6776-7824
ToolGen, Inc.


Atsuko Igawa, 81-3-6832-9446
Thermo Fisher Scientific
Tokyo, JP

Record changed: 2019-06-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Thermo Fisher (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top